Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)

Trial Profile

Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs P-BCMA-101 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Poseida Therapeutics
  • Most Recent Events

    • 17 Apr 2018 Results published in the Poseida Therapeutics Media Release
    • 26 Mar 2018 According to a Poseida Therapeutics media release, initial data from this study has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 18 Dec 2017 According to a Poseida Therapeutics media release, first patient has been treated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top